Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.

<h4>Background</h4>The TLR9 agonist CpG is increasingly applied in preclinical and clinical studies as a therapeutic modality to enhance tumor immunity. The clinical application of CpG appears, however, less successful than would be predicted from animal studies. One reason might be the...

Full description

Saved in:
Bibliographic Details
Main Authors: Stefan Nierkens, Martijn H den Brok, Thijs Roelofsen, Jori A L Wagenaars, Carl G Figdor, Theo J Ruers, Gosse J Adema
Format: article
Language:EN
Published: Public Library of Science (PLoS) 2009
Subjects:
R
Q
Online Access:https://doaj.org/article/9b71579ac2cc4de8ab648b64648303bf
Tags: Add Tag
No Tags, Be the first to tag this record!